Close Menu
Home › FDA Clears GenePOC Group B Streptococcus Assay, MDx Platform

FDA Clears GenePOC Group B Streptococcus Assay, MDx Platform

Jun 01, 2017
|
staff reporter

NEW YORK (GenomeWeb) – GenePOC today said that it has received FDA clearance to market its molecular assay for detecting Group B streptococcus and its Revogene molecular diagnostics instrument in the US.

The test and instrument was launched in Europe earlier in the year.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Nanomix Readying Multimarker Sepsis Test for Use at Point of Care

    Premium

  2. PerkinElmer's Muscular Dystrophy Screening Kit Receives FDA Marketing Authorization

  3. Seventh Sense Biosystems Gets FDA Clearance for At-Home Blood Collection Device

  4. EU Group Issues New IVD Guidelines

  5. Roche Blood Glucose Monitor App Receives CE Mark

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.